相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System
Xiaohui Zeng et al.
CLINICAL THERAPEUTICS (2013)
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
Erzsebet Juhasz et al.
EUROPEAN JOURNAL OF CANCER (2013)
Maintenance Chemotherapy for Advanced Non-Small-Cell Lung Cancer: New Life for an Old Idea
David E. Gerber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)
Fabrice Barlesi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial
Cesare Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer
Maurice Perol et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Safety, Resource Use, and Quality of Life in PARAMOUNT A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Cesare Gridelli et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study
Chandra P. Belani et al.
LANCET ONCOLOGY (2012)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Tudor Ciuleanu et al.
LANCET ONCOLOGY (2012)
A Systemic Approach to Containing Health Care Spending
Ezekiel Emanuel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System
Klazien Matter-Walstra et al.
VALUE IN HEALTH (2012)
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials
Fausto Petrelli et al.
ANTI-CANCER DRUGS (2011)
AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev plus Pemetrexed (pem) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)
F. Barlesi et al.
EUROPEAN JOURNAL OF CANCER (2011)
Pem and the Cost of Multicycle Maintenance
Peter A. Learn et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
Robert Klein et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
Panos M. Fidias et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu et al.
LANCET (2009)
An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
Chris P. Lee et al.
VALUE IN HEALTH (2009)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
T Brodowicz et al.
LUNG CANCER (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life
SG Spiro et al.
THORAX (2004)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
